Axsome Therapeutics, Inc. (AXSM)
142.20
-1.86
(-1.29%)
USD |
NASDAQ |
Oct 27, 16:00
142.22
+0.02
(+0.02%)
After-Hours: 20:00
Axsome Therapeutics Enterprise Value : 7.342B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 7.342B |
| October 26, 2026 | 7.439B |
| October 23, 2026 | 7.490B |
| October 22, 2026 | 8.067B |
| October 21, 2026 | 8.080B |
| October 20, 2026 | 8.251B |
| October 19, 2026 | 8.054B |
| October 16, 2026 | 8.123B |
| October 15, 2026 | 8.366B |
| October 14, 2026 | 8.389B |
| October 13, 2026 | 8.080B |
| October 12, 2026 | 8.587B |
| October 09, 2026 | 8.710B |
| October 08, 2026 | 8.800B |
| October 07, 2026 | 8.951B |
| October 06, 2026 | 9.023B |
| October 05, 2026 | 9.166B |
| October 02, 2026 | 9.280B |
| October 01, 2026 | 9.427B |
| September 30, 2026 | 9.548B |
| September 29, 2026 | 9.640B |
| September 28, 2026 | 10.05B |
| September 25, 2026 | 10.11B |
| September 24, 2026 | 10.16B |
| September 23, 2026 | 10.02B |
| Date | Value |
|---|---|
| September 22, 2026 | 10.53B |
| September 21, 2026 | 10.65B |
| September 18, 2026 | 10.77B |
| September 17, 2026 | 11.11B |
| September 16, 2026 | 10.99B |
| September 15, 2026 | 10.58B |
| September 14, 2026 | 11.23B |
| September 11, 2026 | 11.45B |
| September 10, 2026 | 10.95B |
| September 09, 2026 | 10.92B |
| September 08, 2026 | 10.77B |
| September 04, 2026 | 10.71B |
| September 03, 2026 | 10.80B |
| September 02, 2026 | 10.88B |
| September 01, 2026 | 10.51B |
| August 31, 2026 | 10.29B |
| August 28, 2026 | 10.31B |
| August 27, 2026 | 10.69B |
| August 26, 2026 | 10.74B |
| August 25, 2026 | 10.65B |
| August 24, 2026 | 10.65B |
| August 21, 2026 | 10.77B |
| August 20, 2026 | 10.78B |
| August 19, 2026 | 11.32B |
| August 18, 2026 | 11.19B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.253T |
| Filana Therapeutics, Inc. | -51.36M |
| CorMedix, Inc. | 509.14M |
| Eloxx Pharmaceuticals, Inc. | -8.120M |
| Breakthrough Chemistry, Inc. | 0.241M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.31M |
| Revenue (Quarterly) | 218.38M |
| Total Expenses (Quarterly) | 269.69M |
| EPS Diluted (Quarterly) | -0.9906 |
| Gross Profit Margin (Quarterly) | 92.47% |
| Profit Margin (Quarterly) | -23.50% |
| Earnings Yield | -2.64% |
| Normalized Earnings Yield | -2.611 |